Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases

Doorduyn, Y.; Pelt, Wilfrid van; Siezen, Christine L. E.; Horst, F. Van Der; Duynhoven, Y. T. H. P. Van; Hoebee, Barbara; Janssen, Riny

doi:10.1017/s095026880700996x

Cited by 82 publications

(63 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent follow-up study, 3 years after a casecontrol study on laboratory-confirmed cases of Campylobacter and Salmonella, an increased risk of IBS could not be confirmed [33]. In contrast, the results of this study suggested that patients with IBS or with another chronic intestinal condition were more susceptible to IID.…”

Section: Discussioncontrasting

confidence: 84%

Disease burden of post-infectious irritable bowel syndrome in The Netherlands

et al. 2010

View full text Add to dashboard Cite

SUMMARYPost-infectious irritable bowel syndrome (PI-IBS) has been established as a sequel of infectious intestinal disease (IID). The aim of this study was to estimate the burden of PI-IBS caused by the pathogens Campylobacter, Salmonella and Shigella, and to compare this with other outcomes associated with these pathogens. The attributable risk of PI-IBS due to bacterial pathogens was calculated and linked to national data on gastroenteritis incidence and measures for severity and duration of illness in order to estimate the burden of PI-IBS. One year post-infection, IBS developed in 9 % of patients with bacterial IID. The burden of PI-IBS adds over 2300 disability adjusted life years to the total annual disease burden for the selected pathogens. PI-IBS is a frequent sequel of IID, resulting in a considerable disease burden compared to other outcomes. If this relationship is not considered, this will result in an underestimation of the disease burden of IID.

show abstract

Section: Discussioncontrasting

confidence: 84%

Disease burden of post-infectious irritable bowel syndrome in The Netherlands

et al. 2010

View full text Add to dashboard Cite

show abstract

“…2 Treatment with inhibitors of gastric acid secretion leads to insufficient elimination of several ingested pathogens. [3][4][5][6][7][8][9][10][11] Many studies show that these drugs facilitate the onset of infections in adults [3][4][5][6][7]12 and children, as we recently demonstrated. 10 There is evidence of an increased risk of infections and necrotizing enterocolitis (NEC) related to the use of histamine-2 receptor (H2-R) blockers and proton pump inhibitors in neonates.…”

mentioning

confidence: 56%

Ranitidine is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns

et al. 2012

View full text Add to dashboard Cite

WHAT'S KNOWN ON THIS SUBJECT: Although still off-label for newborns, the use of inhibitors of gastric acid secretion continues to increase. Acid-suppressive drugs could facilitate the onset of infections in adults and children. Evidence for efficacy is weak in newborns, particularly if preterm. WHAT THIS STUDY ADDS:This is the first prospective study demonstrating an association between the use of ranitidine and infections, necrotizing enterocolitis, and fatal outcome in very low birth weight newborns. Caution is advocated in using ranitidine in newborns.abstract BACKGROUND AND OBJECTIVES: Gastric acidity is a major nonimmune defense mechanism against infections. The objective of this study was to investigate whether ranitidine treatment in very low birth weight (VLBW) infants is associated with an increased risk of infections, necrotizing enterocolitis (NEC), and fatal outcome. METHODS:Newborns with birth weight between 401 and 1500 g or gestational age between 24 and 32 weeks, consecutively observed in neonatal intensive care units, were enrolled in a multicenter prospective observational study. The rates of infectious diseases, NEC, and death in enrolled subjects exposed or not to ranitidine were recorded. RESULTS:We evaluated 274 VLBW infants: 91 had taken ranitidine and 183 had not. The main clinical and demographic characteristics did not differ between the 2 groups. Thirty-four (37.4%) of the 91 children exposed to ranitidine and 18 (9.8%) of the 183 not exposed to ranitidine had contracted infections (odds ratio 5.5, 95% confidence interval 2.9-10.4, P , .001). The risk of NEC was 6.6-fold higher in ranitidine-treated VLBW infants (95% confidence interval 1.7-25.0, P = .003) than in control subjects. Mortality rate was significantly higher in newborns receiving ranitidine (9.9% vs 1.6%, P = .003).CONCLUSIONS: Ranitidine therapy is associated with an increased risk of infections, NEC, and fatal outcome in VLBW infants. Caution is advocated in the use of this drug in neonatal age. Infections are a common cause of morbidity and mortality in premature infants. 1 Gastric juice is a major nonimmune defense mechanism against infections. 2 Treatment with inhibitors of gastric acid secretion leads to insufficient elimination of several ingested pathogens. [3][4][5][6][7][8][9][10][11] Many studies show that these drugs facilitate the onset of infections in adults [3][4][5][6][7]12 and children, as we recently demonstrated. 10 There is evidence of an increased risk of infections and necrotizing enterocolitis (NEC) related to the use of histamine-2 receptor (H2-R) blockers and proton pump inhibitors in neonates. [13][14][15] These medications, like many others administered in neonatology, have not been approved by the US Food and Drug Administration for use in this population and are prescribed in an off-label manner because of the perceived safety and potential benefit demonstrated for older populations. Despite these aspects, the use of these drugs has progressively increased. 12,16 In the NICU, the most common i...

show abstract

“…It is also clear that the acidity of the stomach is a crucial early defense mechanism against Campylobacter, although this is not specific for Campylobacter and has also been observed for other pathogens such as Salmonella (50,51).…”

Section: Epidemiological Observationsmentioning

confidence: 99%

“…This is clearly an effective barrier, since patients that use proton pump inhibitors are more susceptible to Campylobacter infection (51,121). In the intestine, Campylobacter has evolved strategies to circumvent the induction of innate immunity.…”

Section: Innate Immunity To Campylobactermentioning

confidence: 99%

Host-Pathogen Interactions inCampylobacterInfections: the Host Perspective

et al. 2008

View full text Add to dashboard Cite

SUMMARY Campylobacter is a major cause of acute bacterial diarrhea in humans worldwide. This study was aimed at summarizing the current understanding of host mechanisms involved in the defense against Campylobacter by evaluating data available from three sources: (i) epidemiological observations, (ii) observations of patients, and (iii) experimental observations including observations of animal models and human volunteer studies. Analysis of available data clearly indicates that an effective immune system is crucial for the host defense against Campylobacter infection. Innate, cell-mediated, and humoral immune responses are induced during Campylobacter infection, but the relative importance of these mechanisms in conferring protective immunity against reinfection is unclear. Frequent exposure to Campylobacter does lead to the induction of short-term protection against disease but most probably not against colonization. Recent progress in the development of more suitable animal models for studying Campylobacter infection has opened up possibilities to study the importance of innate and adaptive immunity during infection and in protection against reinfection. In addition, advances in genomics and proteomics technologies will enable more detailed molecular studies. Such studies combined with better integration of host and pathogen research driven by epidemiological findings may truly advance our understanding of Campylobacter infection in humans.

show abstract

Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases

Cited by 82 publications

References 35 publications

Disease burden of post-infectious irritable bowel syndrome in The Netherlands

Disease burden of post-infectious irritable bowel syndrome in The Netherlands

Ranitidine is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns

Host-Pathogen Interactions inCampylobacterInfections: the Host Perspective

Contact Info

Product

Resources

About